Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume

J Opioid Manag. 2017 May/Jun;13(3):157-168. doi: 10.5055/jom.2017.0383.

Abstract

Objective: The Food and Drug Administration approved the extended-release/long-acting (ER/LA) opioid analgesics risk evaluation and mitigation strategies (REMS) in July 2012 to educate healthcare providers and patients about safe and appropriate opioid analgesic use. The authors evaluated the impact of the REMS on ER/LA opioid analgesic utilization, overall and stratified by patient characteristics and prescriber type associated with greater expected need for analgesia.

Design: Retrospective repeated cross-sectional study. QuintilesIMS's National Prescription Audit™ and LifeLink™ patient-level longitudinal prescription databases measured prescription volumes, projected to national estimates.

Main outcome measures: Changes were assessed in ER/LA opioid analgesic prescriptions dispensed from the 2-year pre-REMS implementation (July 2010 to June 2012) to the 18-month post-REMS implementation (July 2013 to December 2014) periods (with 12-month transitional implementation period in between).

Results: Average quarterly ER/LA opioid prescription volume significantly decreased by 4.3 percent from Preimple-mentation to the Active Period (5.58 vs 5.34 million, p < 0.001). Differences in prescription volume change were observed between age, gender, and payer types. Prescription volume either significantly decreased or remained stable from Preimplementation to the Active Period among most provider specialties evaluated. The largest volume decreases were observed for dentists (-48.5 percent) and emergency medicine specialists (-25.5 percent) (both p < 0.001). The largest increases were observed for nurse practitioners (+33.7 percent) and physician assistants (+31.2 percent; both p < 0.001), whose overall prescribing of nonopioid medications also increased.

Conclusions: A significant decrease in dispensed ER/LA opioid prescriptions was observed following REMS implementation compared to Preimplementation. The impact on volume varied by patient characteristics and prescriber specialty. The REMS program, in conjunction with other healthcare policies and initiatives, likely influenced these observations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Analgesics, Opioid / adverse effects*
  • Analgesics, Opioid / chemistry
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Delayed-Action Preparations
  • Drug Compounding
  • Drug Prescriptions
  • Drug and Narcotic Control / legislation & jurisprudence
  • Drug and Narcotic Control / trends*
  • Emergency Medicine / trends
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Nurse Practitioners / trends
  • Opioid-Related Disorders / prevention & control*
  • Physician Assistants / trends
  • Practice Patterns, Dentists' / trends
  • Practice Patterns, Nurses' / trends
  • Practice Patterns, Physicians' / trends
  • Prescription Drugs / adverse effects*
  • Prescription Drugs / chemistry
  • Program Evaluation
  • Retrospective Studies
  • Risk Evaluation and Mitigation* / legislation & jurisprudence
  • Risk Factors
  • United States
  • Young Adult

Substances

  • Analgesics, Opioid
  • Delayed-Action Preparations
  • Prescription Drugs